Radioiodine treatment for nontoxic multinodular goiter

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1313-1316

  Maurer, Alan H ^a,b   Charkes, N David ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

131I therapy; Multinodular goiter

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROID HORMONE;

HORMONE INHIBITION; HUMAN; HYPOTHYROIDISM; IODINE DEFICIENCY; NODULAR GOITER; PRIORITY JOURNAL; REVIEW; THYROID SURGERY; TREATMENT INDICATION;

GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES;

EID: 0032841163     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. 131I treatment of nodular non-toxic goitre. Eur J Endocrinol. 1996;134:15-20.
2. Huysmans D, Hermus A, Edelbroek M, Barentsz J, Corstens F, Kloppenborg P. Radioiodine for nontoxic multinodular goiter. Thyroid. 1997;7:235-239.
3. Eastman CJ, Phillips DW. Endemic goitre and iodine deficiency disorders: etiology, epidemiology and treatment. Bailliere's Clin Endocrinol Metab. 1988;2: 719-728.
4. Vander JB, Gaston EA, Dawber TR. The significance of non-toxic nodules. Ann Intern Med. 1968;69:537-540.
5. World Health Organization. Fact Sheet No. 121. Geneva, Switzerland: World Health Organization; 1996.
6. Burgi H, Supersaxo Z, Selz B. Iodine deficiency diseases in Switzerland one hundred years after Theodor Kocher's survey: a historical review with some new goitre prevalence data. Acta Endocrinologica. 1990;123:577-590.
7. Rasmussen LB, Andersson G, Garaldsdottir J, et al. Iodine. Do we need an enrichment program in Denmark? Int J Food Sciences Nutr. 1996;47:377-381.
8. Burgi H. Iodization of salt: legislation in Europe. 1992;8:24-25.
9. Kusic Z. Epidemiology of endemic goiter in the former Yugoslavia. Int Counc Control Iodine Def Dis Newsletter. 1992;8:20-21.
10. Parma J, Duprez L, VanSande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993;365:649-651.
11. Karga H, Lee JK, Vickery AL, et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73:832-836.
12. Dumont JE, Lamy F, Roger P, et al. Physiology and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 1992;72:567-697.
13. Parker JL, Ratcliffe JG, Alexander WD. Sporadic non-toxic goitre. A long-term follow-up of 36 patients. Acta Endocrinologica. 1977;85:497-507.
14. Hegedus L, Hansen JM, Feldt-Rasmussen U, Hansen BM, Hoier-Madsen M. Influence of thyroxine treatment on thyroid size and anti-thyroid peroxidase antibodies in Hashimoto's thyroiditis. Clin Endocrinol. 1991;35:235-238.
15. Astwood EB, Cassidy CE, Aurbach GD. Treatment of goiter and thyroid nodules with thyroid. JAMA. 1960;174:459-464.
16. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic nontoxic goiter. Lancet. 1990;336:193-197.
17. Greer MA, Astwood EB. Treatment of simple goiter with thyroid. J Clin Endocrinol Metab. 1953;13:1312-1331.
18. Shimaoka K, Sokal JE. Suppressive therapy of nontoxic goiter. Am J Med. 1974;57:576-583.
19. Perrild H, Hansen JM, Hegedus L, et al. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasound scanning. Acta Endocrinologica (Copenhagen). 1982;100:282-287.
20. Berglund J, Bondesson L, Christensen SB, et al. Indications for thyroxine therapy after surgery for non-toxic benign goitre. Acta Chir Scand. 1990;156:433-438.
21. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules. N Engl J Med. 1987;317:70-75.
22. Hegedus L, Bennedbaek FN. Radioiodine for non-toxic diffuse goiter. Lancet. 1997;350:409-410.
23. Bistrup C, Nielsen JD, Gregersen G, Franch P. Preventive effect of levothyroxine in patients operated for non-toxic goitre: a randomized trial of one hundred patients with nine years follow-up. Clin Endocrinol. 1994;40:323-327.
24. Geerdsen JP, Frolund L. Recurrence of nontoxic goitre with and without postoperative thyroxine medication. Clin Endocrinol. 1984;21:529-533.
25. Geerdsen JP, Frolund L. Thyroid function after surgical treatment of nontoxic goitre. A randomized study of postoperative thyroxine administration. Acta Med Scanda. 1986;220:341-345.
26. Feldkamp J, Seppel T, Becker A, et al. Iodide or L-thyroxine to prevent recurrent goiter in an iodine-deficient area: prospective sonographic study. World J Surg. 1997;21:10-14.
27. Hegedus L, Hansen JM, Veiergang D, Karstrup S. Does prophylactic thyroxine treatment after operation for non-toxic goitre influence thyroid size? BMJ Clin Res Ed. 1987;294:801-803.
28. Miccoli P, Antonelli A, Iacconi P. Prospective, randomized double blind study about effectiveness of levothyroxine suppressive therapy in prevention of recurrence after operation: result at the third year of follow-up. Surgery. 1993;114:1097-1102.
29. From GL, Lawson VG. Multinodular goiter. In: Falk SA, ed. Thyroid Disease: Endocrinology, Surgery, Nuclear Medicine, and Radiotherapy. Philadelphia, PA: Lippincott-Raven; 1997:437-438.
30. Yamashita H, Noguchi S, Watanabe S, et al. Thyroid cancer associated with adenomatous goiter: an analysis of the incidence and clinical factors. Surg Today. 1997;27:495-499.
31. Galanti MR, Sparen P, Karlsson A, Grimelius L, Ekbom A. Is residence in areas of endemic goiter a risk factor for thyroid cancer? Int J Cancer. 1995;61:615-621.
32. Hurley DL, Gharib H. Evaluation and management of multinodular goiter. Otolaryngol Clin North Am. 1996;29:527-540.
33. Berghout A, Wiersinga WM, Drexhage HA, et al. The long-term outcome of thyroidectomy for sporadic non-toxic goitre. Clin Endocrinol. 1989;31:193-199.
34. Rojdmark J, Jarhult J. High long-term recurrence rate after subtotal thyroidectomy for nodular goitre. Eur J Surg. 1995;161:725-726.
35. Beahrs OH, Vandertoll DJ. Complications of secondary thyroidectomy. Surg Gynecol Obstet. 1963;17:535-539.
36. Seiler CA, Glaser C, Wagner HE. Thyroid gland surgery in an endemic region. World J Surg. 1996;20:593-596.
37. Khadra M, Delbridge L, Reeve TS, Poole AG, Crammer P. Total thyroidectomy: its role in the management of thyroid disease. Austral NZ J Surg. 1992;62:91-95.
38. Klein B, Klein E, Horster FA. Results of fractionated radioiodine therapy in 696 patients with hyperthyroidism and 690 patients with non-toxic goiter [in German]. Nuclearmedizin. 1989;28:129-136.
39. VonKeiderling W, Emrich D, Hauswaldt C, Hoffmann G. Outcome of radioiodine radiation therapy of euthyroid goiter [in German]. Dtsch Med Wochenschr. 1964;89:453-457.
40. 131I treatment of benign goiters in an endemic area in southern Bavaria [in German]. Fortschr Röntgenstr. 1979;130:172-174.
41. Olsen KJ. Scintigraphic estimation of thyroid volume and dose distribution at treatment with I-131. Acta Radiol. 1978;17:74-80.
42. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med. 1993;34:1632-1638.
43. Himanka E, Larsson L-G. Estimation of thyroid volume. An anatomic study of the correlation between the frontal silhouette and the volume of the gland. Acta Radiol. 1955;61:125-131.
44. Kelly FJ. Observations on the calculation of thyroid weight using empirical formulae. Clin Endocrinol Metab. 1954;14:326-335.
45. Myhill J, Reeve TS, Figgis PM. Measurement of the mass of the thyroid gland in vivo. AJR. 1965;94:828-836.
46. Hulse R, Wolf R, Fischer J, Gamm H, Hahn K. Determination of organ volume by scintigraphy and echolaminography. In: International Atomic Energy Agency. Medical Radioisotope Scintigraphy. Vienna, Austria: International Atomic Energy Agency; 1973:129-137.
47. Hakman ME, Pameljer FA, Klerk JD, et al. Volume reduction in non-toxic goiter after iodine I-131 therapy, measured by thyroid scintigraphy and CT [abstract]. J Nucl Med. 1994;35:163P.
48. Burkinshaw L. A method of measuring the mass of the thyroid gland in vivo. Acta Radiol. 1958;49:308-320.
49. Huysmans DA, deHaas MM, vandenBroek WJ, et al. Magnetic resonance imaging for volume estimation of large multinodular goitres: a comparison with scintigraphy. Br J Radiol. 1994;67:519-523.
50. Wanet PM, Sand A, Abramovici J. Physical and clinical evaluation of high-resolution thyroid pinhole tomography. J Nucl Med. 1996;37:2017-2020.
51. Ott RJ, Batty V, Webb S, et al. Measurement of radiation dose to the thryoid using positron emission tomography. Br J Radiol. 1987;60:245-261.
52. Frey P, Townsend D, Flattet A, et al. Tomographic imaging of human thyroid using 124-1. J Clin Endocrinol Metab. 1986;63:918-927.
53. Nygaard B, Faber J, Hegedus L. Acute changes in thyroid volume and function following I-131 therapy of multinodular goitre. Clin Endocrinol. 1994;41:715-718.
54. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ. 1993;307:828-832.
55. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121:757-762.
56. Hegedus L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ. 1988;297:661-662.
57. Wesche MF, Tiel-vanBull MM, Smits NJ, Wiersinga WM. Reduction in goiter size by I-131 therapy in patients with non-toxic multinodular goiter. Eur J Endocrinol. 1995;132:86-87.
58. deKlerk JM, vanIsselt JW, vanDijk A, et al. Iodine-131 therapy in sporadic nontoxic goiter. J Nucl Med. 1997;38:372-376.
59. Verelst J, Bonnyns M, Glinoer D. Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinol (Copenh). 1990;122:417-421.
60. Kay TW, d'Emden MC, Andrews JT, Martin FI. Treatment of non-toxic multinodular goiter with radioactive iodine. Am J Med. 1988;84:19-22.
61. Nygaard B, Farber J, Veje A, Hansen JE. Thyroid volume and function after I-131 treatment of diffuse non-toxic goitre. Clin Endocrinol. 1997;46:493-496.
62. Jarlov AE, Faber J, Hegedus L, Hansen JM. Subtle changes in serum thyrotrophin (TSH) and sex-hormone-binding globulin (SHBG) levels during long-term follow-up after radioactive iodine in multinodular non-toxic goitre. Clin Endocrinol. 1992;37:335-337.
63. Huysmans AK, Hermus RM, Edelbroek MA, et al. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters. Thyroid. 1997;7:535-539.
64. Huysmans D, Buijs W, Ven Mvd, et al. Dosimetry and risk estimates of radioiodine therapy used for large, multinodular goiters. J Nucl Med. 1996;37:2072-2079.